Linvoseltamab versus real‑world International Myeloma Working Group standard‑of‑care in triple‑class exposed relapsed/refractory multiple myeloma

Rákkutatás · Multiple myeloma

Linvoseltamab had a higher objective response rate (weighted odds ratio 3.0 [95% confidence interval (CI): 1.9–4.1]) and longer median progression‑free survival (weighted hazard ratio [wHR] 0.33 [95% CI: 0.28–0.40]), time to next treatment (wHR 0.34 [95% CI: 0.29–0.44]), and overall survival (wHR 0.72 [95% CI: 0.58–0.98]) than RW SOC.

Linvoseltamab, a BCMA×CD3 bispecific antibody, was evaluated in the Phase 2 LINKER‑MM1 trial (N = 105, 200 mg dose) in patients with relapsed/refractory multiple myeloma (RRMM) who were triple‑class exposed (TCE) or triple‑class refractory (TCR). The real‑world external control arm (ECA) comprised 203 patients from International Myeloma Working Group sites who met the same eligibility criteria. Inverse probability of treatment weighting was used to balance baseline characteristics. Linvoseltamab showed a higher objective response rate (weighted OR = 3.0; 95 % CI 1.9–4.1) and longer median progression‑free survival (weighted HR = 0.33; 95 % CI 0.28–0.40), time to next treatment (weighted HR = 0.34; 95 % CI 0.29–0.44), and overall survival (weighted HR = 0.72; 95 % CI 0.58–0.98) compared with real‑world standard‑of‑care. These results support linvoseltamab as an effective treatment option for triple‑class exposed/refractory RRMM.

Demonstrating superior efficacy of linvoseltamab over real‑world standard‑of‑care in triple‑class exposed/refractory patients provides evidence that the bispecific antibody can improve clinical outcomes in a population with very limited treatment options.

Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.

Eredeti forrás

Kapcsolódó jelek